

Information for Connecticut Prescribers of Prescription Drugs

Taltz® (ixekizumab)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST ¹
Taltz®	ixekizumab	80 mg	Autoinjector	1	0002-1445-11	\$7,624.59
		80 mg	Autoinjector	2	0002-1445-27	\$15,249.16
		80 mg	Autoinjector	3	0002-1445-09	\$22,873.75
		80 mg	Prefilled Syringe	1	0002-7724-11	\$7,624.59
		20 mg/0.25 mL	Prefilled Syringe	1	0002-8900-11	\$7,624.59
		40 mg/0.5 mL	Prefilled Syringe	1	0002-8905-11	\$7,624.59

In adult patients with moderate to severe plaque psoriasis, (excluding psoriasis involving the genital area) there were no identified differences among race in response to Taltz® (ixekizumab) at Week 12.²

Taltz® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

¹ Source: AnalySource®. Accessed on 01/06/2026. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2026. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

² US Taltz Prescribing Information.